ZVRA vs. DSGN, VERU, GTHX, ELYM, TELO, TRVI, LFCR, ALIM, ACRV, and PRLD
Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Design Therapeutics (DSGN), Veru (VERU), G1 Therapeutics (GTHX), Eliem Therapeutics (ELYM), Telomir Pharmaceuticals (TELO), Trevi Therapeutics (TRVI), Lifecore Biomedical (LFCR), Alimera Sciences (ALIM), Acrivon Therapeutics (ACRV), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:ZVRA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
Zevra Therapeutics received 3 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Zevra Therapeutics an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
In the previous week, Design Therapeutics had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 11 mentions for Design Therapeutics and 10 mentions for Zevra Therapeutics. Design Therapeutics' average media sentiment score of 0.45 beat Zevra Therapeutics' score of -0.18 indicating that Design Therapeutics is being referred to more favorably in the news media.
Zevra Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.
Zevra Therapeutics presently has a consensus price target of $19.50, indicating a potential upside of 280.86%. Design Therapeutics has a consensus price target of $6.60, indicating a potential upside of 38.36%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Design Therapeutics.
Design Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -167.69%. Design Therapeutics' return on equity of -22.82% beat Zevra Therapeutics' return on equity.
35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 25.7% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Zevra Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Zevra Therapeutics beats Design Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Zevra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevra Therapeutics Competitors List
Related Companies and Tools
